Mirror-Image meth: scientists compare two forms of the drug
NCT ID NCT06746831
First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 5 times
Summary
This study will give 17 healthy adults three different versions of methamphetamine to see how the body processes each one. Meth comes in two mirror-image forms: S-meth, a strong stimulant used for ADHD, and R-meth, a weaker form found in some nasal sprays. Researchers will measure drug levels in blood, urine, and saliva, and test thinking skills after each dose.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- S-(+)-methamphetamine and R-(-)-methamphetamine
- What this could lead to
- If successful, this could help understand how different forms of methamphetamine affect people, potentially informing safer use or new treatments.
- What could go wrong
- This is a very small, early-stage study in healthy volunteers, not patients. It measures drug effects in a lab setting, so results may not apply to real-world use or lead to any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 17 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Good mental health as determined by self-reported responses to the Psychopathology Screener * Absence of any major cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal, or hepatic disease as determined by self-reported responses to the Medical History Screener * English-speaking (able to provide consent and complete questionnaires) * Written Informed Consent Exclusion Criteria: * Any serious prior adverse response to sympathomimetic agents or amphetamine analogs * History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener * Pregnancy or lactation (pregnancy test, if needed) * Use of medications that may impact cognition or metabolism (e.g., mood stabilizers, sedatives) * Dependent on prohibited concomitant therapy that cannot be withheld for 48 hours prior to and during study visits.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Methamphetamine are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Wisconsin
Madison, Wisconsin, 53705, United States